| Old Articles: <Older 17881-17890 Newer> |
|---|
 |
The Motley Fool
October 30, 2006 |
Coventry's Healthy Results: Fool by Numbers The regional health management company released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...   |
The Motley Fool
October 30, 2006
Rich Smith |
Foolish Forecast: Superior Guesstimates With General Motors projecting a 12% cut in output next quarter, Ford 21%, and DaimlerChrysler on its way to cutting 16% this fiscal half, things are looking bleak for wheelmaker Superior Industries. The upcoming third-quarter results should tell us exactly how bleak. |
The Motley Fool
October 30, 2006
Brian Lawler |
Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note. |
The Motley Fool
October 30, 2006
Tim Beyers |
APC Loses Power After years of poor results, American Power Conversion submits to a buyout by French electrical equipment maker Schneider Electric. Investors, this is a mistake. |
The Motley Fool
October 30, 2006
Jeremy MacNealy |
Fool on Call: Avid Maximizes Opportunities There is hope that a new operational model will not only improve service but also increase profits for the digital media specialist. Here's the inside scoop from the company's third-quarter conference call. Investors, take note. |
The Motley Fool
October 30, 2006
Rich Duprey |
K2 Bundles Up for Winter: Fool by Numbers The sporting goods manufacturer released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
October 30, 2006
Steven Mallas |
"Saw" Still Cutting It? Blood and bodies still equal bucks. There's no stopping Jigsaw and and the Saw franchise -- and there's no stopping Lions Gate Entertainment in its quest for future cash flow. Investors, take note. |
The Motley Fool
October 30, 2006
Brian Lawler |
Sales Slow Down for Bristol-Myers Plavix isn't the only drug facing a challenging future. Losing patent protection and facing generic competition can be disastrous to sales and earnings if a pharmaceutical company doesn't have a way to drive revenue growth. Investors, take note. |
The Motley Fool
October 30, 2006
S.J. Caplan |
Scouting the Latest IPOs An investor's roundup of new-issue hits, misses, and no-shows. Home Inns & Hotel Management... Gatehouse Media... Douglas Emmett... Achillion Pharmaceuticals... etc. |
The Motley Fool
October 30, 2006
Brian Lawler |
Millennium Is So Last Century The drug company released its third-quarter results last week, and there is not much particularly exciting therein. None of its drug candidates is in late-stage testing and all are years away from approval, except for follow-on indications for Velcade. Investors, take note. |
| <Older 17881-17890 Newer> Return to current articles. |
